(NP (NP (NP (NN Ablation)) (PP (IN of) (NP (NP (VBN transplanted) (ADJP (NN HTLV-I) (JJ Tax-transformed)) (NNS tumors)) (PP (IN in) (NP (NNS mice))))) (PP (IN by) (NP (NP (JJ antisense) (NN inhibition)) (PP (IN of) (NP (NN NF-kappa) (NN B)))))) (S (-LRB- -LCB-) (NP-SBJ (VBN published) (NN erratum)) (VP (VBZ appears) (PP (IN in) (NP (NNP Science) (CD 1993) (NNP Mar) (CD 12) (: ;) (CD 259) (-LRB- -LRB-) (CD 5101) (-RRB- -RRB-) (: :) (CD 1523)))) (-RRB- -RCB-)))
(S (NP-SBJ (NP (NNS Mice)) (ADJP (JJ transgenic) (PP (IN for) (NP (DT the) (NP (NP (JJ human) (NN T) (NN cell) (NN leukemia) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HTLV-I)) (-RRB- -RRB-))) (NN Tax) (NN gene))))) (VP (VBP develop) (NP (NP (JJ fibroblastic) (NNS tumors)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ (-NONE- *T*-1)) (VP (VBP express) (NP (ADJP (NN NF-kappa) (JJ B-inducible)) (JJ early) (NNS genes))))))) (. .))
(S (NP-SBJ (NP (ADJP (FW In) (FW vitro)) (NN inhibition)) (PP (IN of) (NP (NN NF-kappa) (NN B) (NN expression))) (PP (IN by) (NP (JJ antisense) (NP (NP (NNS oligodeoxynucleotides)) (PRN (-LRB- -LRB-) (NP (NNS ODNs)) (-RRB- -RRB-)))))) (VP (VBD inhibited) (NP (NP (NN growth)) (PP (IN of) (NP-COOD (NP (DT these) (JJ culture-adapted) (JJ Tax-transformed) (NNS fibroblasts)) (CONJP (RB as) (RB well) (IN as)) (NP (DT an) (JJ HTLV-I-transformed) (JJ human) (NN lymphocyte) (NN line)))))) (. .))
(S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (JJ antisense) (NN inhibition)) (PP (IN of) (NP (NP (NN Tax)) (NP (PRP itself))))) (VP (VBD had) (NP (DT no) (JJ apparent) (NN effect)) (PP (IN on) (NP (NN cell) (NN growth)))) (. .))
(S (NP-SBJ (NP (NNS Mice)) (VP (VBN treated) (NP (-NONE- *)) (PP (IN with) (NP (NP (NN antisense)) (PP (TO to) (NP (NN NF-kappa) (NN B) (NNS ODNs))))))) (VP (VBD showed) (NP (NP (JJ rapid) (NN regression)) (PP (IN of) (NP (VBN transplanted) (NNS fibrosarcomas))))) (. .))
(S (NP-SBJ (DT This)) (VP-COOD (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ (NN NF-kappa) (NN B) (NN expression)) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ necessary) (PP (IN for) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (DT the) (JJ malignant) (NN phenotype))))))))))) (CC and) (VP (VBZ provides) (NP (NP (DT a) (JJ therapeutic) (NN approach)) (PP (IN for) (NP (JJ HTLV-I-associated) (NN disease)))))) (. .))
